Nilotinib treatment-associated accelerated atherosclerosis: when is the risk justified?

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Leukemia 2013-09, Vol.27 (9), p.1939-1940
1. Verfasser:	Tefferi, A
Format:	Artikel
Sprache:	eng
Schlagworte:	692/699/67/1059/99 692/699/67/1990/283/1896 692/699/75/593/2100 692/700/565/2194 Antineoplastic Agents - adverse effects Arterial Occlusive Diseases - complications Atherosclerosis Benzamides - adverse effects Cancer Research Cardiovascular disease Complications and side effects Critical Care Medicine Dosage and administration Heart attacks Hematology Humans Intensive Internal Medicine Kinases Letter to the Editor Letters to the editor Leukemia Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy Medicine Medicine & Public Health Nilotinib Oncology Peripheral Arterial Disease - complications Piperazines - adverse effects Pyrimidines - adverse effects Remission (Medicine) Risk factors
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!